Stocktoria
Nasus Pharma Ltd NSRX
NYSE American · XASE · stock · Pharmaceutical Preparations · website · IPO 2025-08-13
Nasus Pharma Ltd statistics & valuation
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 |
|---|---|---|
| Operating margin | -0.4% | — |
| Net margin | -0.5% | — |
| FCF margin | -0.4% | — |
| Return on assets | -117.0% | -213.7% |
| Return on equity | -211.6% | 47.7% |
| Current ratio | 2.24 | 0.12 |
Source: SEC EDGAR filings · CIK 0002029039 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.